Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 308

Similar articles for PubMed (Select 12372044)

1.

Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.

Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, Posner MP.

Clin Transplant. 2002;16 Suppl 7:49-51.

PMID:
12372044
2.

Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.

Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.

Transplant Proc. 2008 Jun;40(5):1541-4. doi: 10.1016/j.transproceed.2008.01.081.

PMID:
18589147
3.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

4.

Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.

Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.

Transplant Proc. 2009 Sep;41(7):2789-93. doi: 10.1016/j.transproceed.2009.07.094.

PMID:
19765436
5.

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.

J Heart Lung Transplant. 2005 Dec;24(12):2129-36.

PMID:
16364861
6.

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.

De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.

Liver Transpl. 2009 Oct;15(10):1262-9. doi: 10.1002/lt.21827.

7.

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.

Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.

Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.

8.

Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.

Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.

Transplant Proc. 2009 Mar;41(2):756-63. doi: 10.1016/j.transproceed.2009.01.044.

PMID:
19328973
9.

Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.

Forgacs B, Merhav HJ, Lappin J, Mieles L.

Transplant Proc. 2005 May;37(4):1912-4.

PMID:
15919502
10.

Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.

Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.

Transplantation. 2007 Aug 27;84(4):467-74.

PMID:
17713429
11.

Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.

Flechner SM, Kobashigawa J, Klintmalm G.

Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x. Review.

PMID:
18217899
12.

Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.

Ziolkowski J, Paczek L, Senatorski G, Niewczas M, Oldakowska-Jedynak U, Wyzgal J, Sanko-Resmer J, Pilecki T, Zieniewicz K, Nyckowski P, Patkowski W, Krawczyk M.

Transplant Proc. 2003 Sep;35(6):2307-9.

PMID:
14529923
13.

Conversion to sirolimus in renal transplant recipients: a single-center experience.

Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.

Artif Organs. 2010 Aug;34(8):E230-7. doi: 10.1111/j.1525-1594.2010.01022.x. Epub 2010 Jul 6.

PMID:
20618227
14.
15.

Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience.

Alarrayed SM, El-Agroudy AE, Alarrayed AS, Al Ghareeb SM, Garadah TS, El-Sharqawi SY, Al-Aradi AH, Dandi BG, Abdulla S.

Clin Exp Nephrol. 2010 Jun;14(3):248-55. doi: 10.1007/s10157-010-0269-0. Epub 2010 Mar 16.

PMID:
20232105
16.

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.

Liver Transpl. 2007 Dec;13(12):1694-702.

17.

Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.

Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.

Clin Transplant. 2004;18 Suppl 12:61-6.

PMID:
15217410
18.

Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.

Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ.

J Heart Lung Transplant. 2005 Nov;24(11):1863-7. Epub 2005 Jun 13.

PMID:
16297793
19.

Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.

Gutiérrez MJ, González E, Andrés A, Morales JM.

Transplant Proc. 2009 Jul-Aug;41(6):2348-50. doi: 10.1016/j.transproceed.2009.06.163.

PMID:
19715916
20.

Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.

Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.

Liver Transpl. 2003 Oct;9(10):1079-85.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk